search
Back to results

The Boston Scientific ENOVUS Trial

Primary Purpose

Abdominal Aortic Aneurysm

Status
Withdrawn
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Boston Scientific ENOVUS AAA Endograft
Sponsored by
Boston Scientific Corporation
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Abdominal Aortic Aneurysm focused on measuring Abdominal Aortic Aneurysm, Aortic Aneurysm, AAA, Endovascular, Stent Graft, Endograft, Vascular Prostheses

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: All patients must meet all of the following inclusion criteria to be eligible for enrollment into this study: Patient is > 18 years of age Females of childbearing potential have a negative pregnancy test at the time of treatment Patient has signed an Institutional Review Board (IRB) approved Informed Consent Form Patient is considered by the treating physician to be a candidate (i.e., categories I, II, or III) for elective open surgical repair of the AAA per American Society of Anesthesiology (ASA) refer to Appendix II. ASA grade IV patients may be enrolled provided their life expectancy is greater than 1 year. Patient has an infrarenal abdominal aortic aneurysm that meets at least one of the following:•Abdominal aortic aneurysm >4.5 cm in diameter Aneurysm has increased in size by 0.5 cm in last 6 months. Maximum diameter of aneurysm exceeds one and one-half times the transverse dimension of an adjacent normal aortic segment Patient must be willing to comply with all required follow-up exams (open surgical control patients are followed through one year, Treatment Group patients are followed through five years in the study with lifelong follow up by physician thereafter). Exclusion Criteria: Patients that meet ANY of the following are not eligible for enrollment into the study: Aneurysm dissection Acutely ruptured aneurysm Acute vascular injury Need for emergent surgery Patient has a known thoracic aortic aneurysm or dissection. Patient has unstable angina (defined as angina characterized by progressive increase in anginal symptoms, new onset at rest or nocturnal angina, or onset of prolonged angina) Patient has history of connective tissue disease (e.g., Marfan's or Ehler's-Danlos syndrome). Patient has history of bleeding disorders or refuses blood transfusions. Patient has baseline serum creatinine level >2.0 mg/dl Patient has a known hypersensitivity or contraindication to anticoagulation that is not amenable to pre-treatment. Patient has a mycotic aneurysm or has an active systemic infection Patient is morbidly obese or has other clinical conditions that severely inhibit X-ray visualization of the aorta Patient has a limited life expectancy of less than 1 year Patient is currently participating in another investigational device or drug clinical trial Patient has other medical, social or psychological conditions that, in the opinion of the investigator, preclude them from receiving this treatment, pre-treatment, and post-treatment procedures and evaluations.

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Efficacy will evaluate patients (Treatment Group) free from AAA rupture and surgical conversion within 1 year of the initial procedure.

    Secondary Outcome Measures

    Full Information

    First Posted
    October 27, 2005
    Last Updated
    August 27, 2015
    Sponsor
    Boston Scientific Corporation
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00246038
    Brief Title
    The Boston Scientific ENOVUS Trial
    Official Title
    A Phase II Evaluation of the Safety and Efficacy of the Boston Scientific ENOVUS AAA Endograft in the Treatment of Abdominal Aortic Aneurysms
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2015
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    Sponsor cancelled the development program, and never conducted the study.
    Study Start Date
    undefined (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Name of the Sponsor
    Boston Scientific Corporation

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    A prospective, actively controlled, consecutively enrolling, non-randomized multi center clinical evaluation of the safety and efficacy of the Boston Scientific ENOVUS AAA Endograft when used in the treatment of patients with AAA (Treatment Group) as compared to patients treated with conventional open surgery (Control Group).
    Detailed Description
    The primary objectives of this study are to determine whether the Boston Scientific ENOVUS AAA Endograft is a safe and effective method of treating AAA's in those patients considered to be suitable candidates for open surgical repair. The safety of the Boston Scientific ENOVUS AAA Endograft will be determined by comparing the rate of major morbidity in the Treatment Group against the rate of major morbidity in the Control Group within 30 days of the initial procedure. The efficacy of the Boston Scientific ENOVUS AAA Endograft will be determined by evaluating the proportion of patients in the Treatment Group that are free from AAA rupture and conversion to open surgical repair within 1 year of the initial procedure. The secondary safety endpoints will be compared between the Treatment and Control Groups:Mortality rates at 30 days and 1 year, AAA related mortality at 30 days and 1 year. The secondary efficacy endpoints will be evaluated in the Treatment Group only and include: Technical success, enlargement of AAA, migration, significant endoleak, and loss of device integrity. Secondary Clinical Utility endpoints will be compared between the Treatment and Control groups and will include: blood loss, duration of procedure, ICU stay, length of hospital stay, and duration of anesthesia.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Abdominal Aortic Aneurysm
    Keywords
    Abdominal Aortic Aneurysm, Aortic Aneurysm, AAA, Endovascular, Stent Graft, Endograft, Vascular Prostheses

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Intervention Type
    Device
    Intervention Name(s)
    Boston Scientific ENOVUS AAA Endograft
    Primary Outcome Measure Information:
    Title
    Efficacy will evaluate patients (Treatment Group) free from AAA rupture and surgical conversion within 1 year of the initial procedure.

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: All patients must meet all of the following inclusion criteria to be eligible for enrollment into this study: Patient is > 18 years of age Females of childbearing potential have a negative pregnancy test at the time of treatment Patient has signed an Institutional Review Board (IRB) approved Informed Consent Form Patient is considered by the treating physician to be a candidate (i.e., categories I, II, or III) for elective open surgical repair of the AAA per American Society of Anesthesiology (ASA) refer to Appendix II. ASA grade IV patients may be enrolled provided their life expectancy is greater than 1 year. Patient has an infrarenal abdominal aortic aneurysm that meets at least one of the following:•Abdominal aortic aneurysm >4.5 cm in diameter Aneurysm has increased in size by 0.5 cm in last 6 months. Maximum diameter of aneurysm exceeds one and one-half times the transverse dimension of an adjacent normal aortic segment Patient must be willing to comply with all required follow-up exams (open surgical control patients are followed through one year, Treatment Group patients are followed through five years in the study with lifelong follow up by physician thereafter). Exclusion Criteria: Patients that meet ANY of the following are not eligible for enrollment into the study: Aneurysm dissection Acutely ruptured aneurysm Acute vascular injury Need for emergent surgery Patient has a known thoracic aortic aneurysm or dissection. Patient has unstable angina (defined as angina characterized by progressive increase in anginal symptoms, new onset at rest or nocturnal angina, or onset of prolonged angina) Patient has history of connective tissue disease (e.g., Marfan's or Ehler's-Danlos syndrome). Patient has history of bleeding disorders or refuses blood transfusions. Patient has baseline serum creatinine level >2.0 mg/dl Patient has a known hypersensitivity or contraindication to anticoagulation that is not amenable to pre-treatment. Patient has a mycotic aneurysm or has an active systemic infection Patient is morbidly obese or has other clinical conditions that severely inhibit X-ray visualization of the aorta Patient has a limited life expectancy of less than 1 year Patient is currently participating in another investigational device or drug clinical trial Patient has other medical, social or psychological conditions that, in the opinion of the investigator, preclude them from receiving this treatment, pre-treatment, and post-treatment procedures and evaluations.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Rodney A. White, MD; Chief, Vascular Surgery
    Organizational Affiliation
    University of California, Los Angeles
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    W. Anthony Lee, MD; Assistant Professor of Surgery
    Organizational Affiliation
    University of Florida
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    The Boston Scientific ENOVUS Trial

    We'll reach out to this number within 24 hrs